E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036376 |
E.1.2 | Term | Post herpetic neuralgia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of SLC022 300 mg three times daily (TID) versus placebo TID over 28 days of treatment in subjects with PHN (postherpetic neuralgia). |
|
E.2.2 | Secondary objectives of the trial |
-- To determine the safety and tolerability of SLC022 300 mg three times daily (TID) compared to placebo TID over 28 days of treatment in subjects with PHN (postherpetic neuralgia).
-- To establish a population-based pharmacokinetic (PK) model for comparing inter-subject variances in exposure. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female age 18 years or older.
2. A history of cutaneous herpes zoster infection and sustained pain associated with the site of the herpes zoster skin rash for >6 months, after onset of the herpes zoster skin rash.
3. Pain intensity score of ≥4 on an 11-point numerical rating scale for at least 5 of 7 days immediately prior to randomization.
4. Mean pain intensity of ≥4 on an 11-point numerical rating scale during the Baseline Phase.
5. Completion of at least 5 out of 7 daily pain reports during the Baseline Phase.
6. Completed a washout period of 7 days for any of the following medications: α2-δ antagonists (e.g., gabapentin), opiate analgesics, topical lidocaine, anticonvulsants, TCAs, serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine), skeletal muscle relaxants, orally administered steroids, capsaicin, mexiletene, and centrally acting analgesics (dextromethorphan, tramadol).
7. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
8. A willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. |
|
E.4 | Principal exclusion criteria |
1. Pregnant or breast feeding.
2. Female subjects who are not surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least one year, or are not willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method], unless sexually abstinent).
3. Previous neurolytic or neurosurgical therapy for PHN.
4. Treatment with local anesthetic nerve blocks within the last 30 days.
5. Failure of an adequate dose of 3 or more first line drug treatments for PHN-related pain due to efficacy. First line drug treatments include α2-δ antagonists (gabapentin or pregabalin), SNRIs (e.g., duloxetine), the 5% lidocaine patch, opioid analgesics, tramadol hydrochloride, and TCAs.
6. Any other type of pain which may impair the self assessment of the pain due to PHN.
7. Skin conditions in the affected dermatome that could alter sensation.
8. Participation in other studies within 30 days before the current study begins and/or during study participation.
9. Taking CYP1A2 inhibitors such as fluvoxamine, certain fluoroquinolones (e.g. ciprofloxacin, enoxacin, pefloxacin, etc), mexiletine, and zileuton.
10. History of drug or alcohol abuse during the last 5 years.
11. Creatinine clearance <50 mL/min.
12. History of malignancy (< 5 years since diagnosis) other than basal cell carcinoma and carcinoma in situ.
14. History of chronic hepatitis B or C, or human immunodeficiency virus (HIV) infection.
15. Clinically significant hepatic, respiratory, hematological, cardiovascular or neurological disease.
16. Immunocompromised state.
17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint of this study is the reduction of PHN-related pain as reported on an 11-point numerical pain rating scale via the electronic subject diary. Actual values and change from baseline will be summarized by visit. The mean pain score at the end of the Treatment Phase (last 5 pain scores reported during treatment) will be compared to the mean pain score from baseline (last 5 pain scores reported prior to randomization). An Analysis of Covariance (ANCOVA) with baseline pain as a covariate will be performed on the difference in mean pain from baseline to end of treatment. Primary efficacy analysis will utilize the last observation carried forward (LOCF) imputation methodology outlined below. An observed case analysis using mixed model repeated measures (MMRM) will also be presented as a secondary sensitivity analysis. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient's last visit in the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |